Moderna, Inc. Finance Lease, Right-of-Use Asset, Amortization
Moderna, Inc. (MRNA) reported Finance Lease, Right-of-Use Asset, Amortization of $24.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-20
- Moderna, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2020-12-31 was $447.00K, a 396.67% increase year-over-year.
- Moderna, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2020-09-30 was $368.00K, a 404.11% increase year-over-year.
- Moderna, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2020-06-30 was $112.00K, a 53.42% increase year-over-year.
- Moderna, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2020-03-31 was $73.00K, a 0.00% change year-over-year.
- Moderna, Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $24.00M, a 9.09% increase from fiscal 2024.
- Moderna, Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $22.00M, a 95.60% decline from fiscal 2023.
- Moderna, Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $500.00M, a 78.57% increase from fiscal 2022.
- Moderna, Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $280.00M, a 48.15% increase from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month | Finance Lease, Right-of-Use Asset, Amortization 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $24.00M 10-K · filed 2026-02-20 | ||||
| 2024-12-31 | $22.00M 10-K · filed 2026-02-20 | ||||
| 2023-12-31 | $500.00M 10-K · filed 2026-02-20 | ||||
| 2022-12-31 | $280.00M 10-K · filed 2025-02-21 | ||||
| 2021-12-31 | $189.00M 10-K · filed 2024-02-23 | ||||
| 2020-12-31 | $447.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $815.00K derived: sum of 2 quarters · filed 2023-02-24 | $927.00K derived: sum of 3 quarters · filed 2023-02-24 | $1.00M 10-K · filed 2023-02-24 | $1.01M 10-K · filed 2021-02-26 |
| 2020-09-30 | $368.00K 10-Q · filed 2020-10-30 | $480.00K derived: sum of 2 quarters · filed 2020-10-30 | $553.00K 10-Q · filed 2020-10-30 | $643.00K derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-06-30 | $112.00K 10-Q · filed 2020-08-06 | $185.00K 10-Q · filed 2020-08-06 | $275.00K derived: sum of 3 quarters · filed 2021-02-26 | $348.00K derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-03-31 | $73.00K 10-Q · filed 2020-05-07 | $163.00K derived: sum of 2 quarters · filed 2021-02-26 | $236.00K derived: sum of 3 quarters · filed 2021-02-26 | $309.00K derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $163.00K derived: sum of 2 quarters · filed 2021-02-26 | $236.00K derived: sum of 3 quarters · filed 2021-02-26 | $309.00K 10-K · filed 2021-02-26 | |
| 2019-09-30 | $73.00K 10-Q · filed 2020-10-30 | $146.00K derived: sum of 2 quarters · filed 2020-10-30 | $219.00K 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | $73.00K 10-Q · filed 2020-08-06 | $146.00K 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $73.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |